ClinicalTrials.Veeva

Menu

Organoids for Bile Leaks (ASCORB)

I

Institute of Hospitalization and Scientific Care (IRCCS)

Status and phase

Not yet enrolling
Phase 2

Conditions

Biliary Anastomosis Complication

Treatments

Biological: Organoid-guided treatment

Study type

Interventional

Funder types

Other

Identifiers

NCT07214649
2025001
FPG (Other Identifier)

Details and patient eligibility

About

Background: Bile leakage remains a major complication after hepatobiliary surgery and liver transplantation. While most cases are managed through standard radiologic or endoscopic interventions, a subset of patients fails to respond and may face recurrent interventions or even retransplantation. Recent advances in regenerative medicine, particularly the development of extrahepatic cholangiocyte organoids (ECOs), offer a promising alternative.

Objective: This prospective, 5-year study aims to evaluate the feasibility, safety, and efficacy of autologous ECO-based cell therapy to reconstruct bile ducts in patients with persistent bile leakage unresponsive to standard care.

Methods: Patients undergoing hepatobiliary or liver transplant surgery will have a biopsy of extrahepatic bile duct tissue collected perioperatively. The tissue will be processed and stored in a dedicated biobank. Upon development of a refractory bile leak, ECOs will be generated from the stored tissue and delivered to the site of injury through radiological or endoscopic routes, as decided by a multidisciplinary team. Success will be evaluated by resolution of leakage (radiologically or endoscopically) and absence of further intervention.

Significance: The use of patient-specific ECOs holds transformative potential. Organoids can be derived and expanded in vitro while maintaining cholangiocyte identity and function. Preclinical studies in murine and human models show successful engraftment and functional integration into biliary epithelium.

Expected Outcomes: This project aims to pioneer a novel, minimally invasive, personalized regenerative therapy for otherwise intractable biliary complications.

Enrollment

25 estimated patients

Sex

All

Ages

18 to 99 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age over 18 years old
  • Undergone HPB surgical procedure with hepatic duct reconstruction
  • Presence of anastomotic bile leakage untreatable with radiological or endoscopic approach
  • Presence of bile duct specimen

Exclusion criteria

  • Age under 18 years old
  • Undergone HPB surgical procedure without hepatic duct reconstruction
  • Absence of anastomotic bile leakage untreatable with radiological or endoscopic approach
  • Absence of bile duct specimen

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

25 participants in 1 patient group

Organoid Arm
Experimental group
Treatment:
Biological: Organoid-guided treatment

Trial contacts and locations

0

Loading...

Central trial contact

Marco M Pascale, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems